The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension.

In a retrospective study, we tested the hypothesis that anticoagulant therapy with warfarin sodium (Coumadin) has a beneficial influence on the long-term prognosis in patients with primary pulmonary hypertension (PPH) and aminorex-induced plexogenic pulmonary hypertension. The study included a total of 173 patients from two European cities. One hundred four of these patients took the anorectic drug aminorex (Menocil), which was available in some European countries almost 30 years ago; 69 patients had pulmonary hypertension of unexplained etiology, ie, PPH. Fifty-six of the 104 aminorex-treated patients and 24 patients in the PPH group received warfarin after diagnosis was established. For analysis, patients were divided into four groups according to their history of aminorex intake and anticoagulant therapy. Survival time, changes in hemodynamics (pulmonary arterial pressure), and improvement in quality of life (scored by the New York Heart Association [NYHA] classification) were compared and analyzed. We found that aminorex-treated patients had a better long-term prognosis than those with PPH (7.5 vs 3.9 years; p < or = 0.001). The best mean survival time of 8.3 years was found in anticoagulated aminorex-treated patients, compared to 6.1 years in nonanticoagulated aminorex-treated patients. Moreover, aminorex-treated patients who received anticoagulant therapy soon after the onset of symptoms showed significantly better prognosis (10.9 years) than those who commenced treatment 2 years thereafter (5.9 years) (p < or = 0.05). In patients with PPH, systolic pulmonary pressure was shown to influence survival time significantly (p < or = 0.0005); however, this correlation was not found in aminorex-treated patients. An improvement of symptoms like dyspnea on exertion was seen in 44.8% of the anticoagulated aminorex-treated patients, while deterioration was evident in 72.2% of the nonanticoagulated aminorex-treated patients. In conclusion, our study has shown that anticoagulant therapy had a positive influence on long-term survival and a significant improvement in quality of life in patients with PPH, in particular in patients with a history of anorectic drug intake.

[1]  S. Haworth.  Primary pulmonary hypertension. , 1983, British heart journal.

[2]  S. Rich,et al.  The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.

[3]  A. Jaffe,et al.  Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. , 1990, Circulation.

[4]  H. Baur,et al.  Influence of Warfarin Therapy in Primary Pulmonary Hypertension , 1990 .

[5]  S. Rich.  Primary pulmonary hypertension , 1988 .

[6]  E. Robin.  The kingdom of the near-dead. The shortened unnatural life history of primary pulmonary hypertension. , 1987, Chest.

[7]  B. Brundage,et al.  High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. , 1987, Circulation.

[8]  E. Robin,et al.  PRIMARY PULMONARY HYPERTENSION , 2022 .

[9]  T. Higenbottam,et al.  Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin). , 1987, British heart journal.

[10]  T. Higenbottam.  Primary pulmonary hypertension. , 1986, British medical journal.

[11]  C. Oakley,et al.  Factors that influence the outcome of primary pulmonary hypertension. , 1986, British heart journal.

[12]  J. Mlczoch.  Evolution of Primary Pulmonary Hypertension , 1985 .

[13]  M. Packer,et al.  Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. , 1984, Journal of the American College of Cardiology.

[14]  V. Fuster,et al.  Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.

[15]  T. Higenbottam,et al.  LONG-TERM TREATMENT OF PRIMARY PULMONARY HYPERTENSION WITH CONTINUOUS INTRAVENOUS EPOPROSTENOL (PROSTACYCLIN) , 1984, The Lancet.

[16]  B. Brundage,et al.  Primary pulmonary hypertension. Current update. , 1984, JAMA.

[17]  S. Rich,et al.  Characteristics of surviving and nonsurviving patients with primary pulmonary hypertension. , 1984, The American journal of medicine.

[18]  S. Rich,et al.  Comparative actions of hydralazine, nifedipine and amrinone in primary pulmonary hypertension. , 1983, The American journal of cardiology.

[19]  K. Rosen,et al.  Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response. , 1983, American heart journal.

[20]  B. Massie,et al.  Deleterious effects of hydralazine in patients with pulmonary hypertension. , 1982, The New England journal of medicine.

[21]  M. Rabinovitch,et al.  A case of spontaneous resolution of idiopathic pulmonary hypertension. , 1981, British heart journal.

[22]  R. Peter,et al.  Oral hydralazine therapy for primary pulmonary hypertension. , 1980, The New England journal of medicine.

[23]  P. Probst,et al.  Primary pulmonary hypertension: follow-up of patients with and without anorectic drug intake. , 1980, Cor et vasa.

[24]  Gurtner Hp.  Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? , 1979 .

[25]  A. Perosio,et al.  Long-term follow-up in primary pulmonary hypertension. , 1979, British heart journal.

[26]  H. Gurtner.  Pulmonary hypertension, "plexogenic pulmonary arteriopathy" and the appetite depressant drug aminorex: post or propter? , 1979, Bulletin europeen de physiopathologie respiratoire.

[27]  C. Oakley,et al.  Regression of primary pulmonary hypertension. , 1976, British heart journal.

[28]  N. Nielsen,et al.  Primary pulmonary hypertension. With special reference to prognosis. , 2009, Acta medica Scandinavica.

[29]  D. Wilcken,et al.  Anticoagulant treatment of obliterative pulmonary hypertension. , 1960, Lancet.

[30]  P. Wood.  Diseases of the Heart and Circulation , 1902, The Hospital.